Ascletis says ASC50 cuts PASI score 48.9% in 28-day U.S. plaque psoriasis study

• Ascletis reported positive results from a 28-day U.S. proof-of-concept trial of ASC50 in plaque psoriasis.
• Results were presented with the announcement, not flagged for a future medical meeting.
• Study showed meaningful symptom improvement versus placebo, with effects continuing beyond the final dose.
• Safety profile appeared clean in the short study, with no serious events or liver-related signals reported.
• Drug’s durability supports a potential shift to once-weekly oral dosing, positioning ASC50 as a needle-free alternative to biologics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609282000PR_NEWS_USPR_____CN57860) on September 29, 2026, and is solely responsible for the information contained therein.